Who are MaaT013's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fecal Microbiota Transplantation, Human fecal microbiota, MBiotix HBI, Fecal Microbial Transplantation, Fecal transplantation, Encapsulated FMT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/maat013.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

MaaT013 — Competitive Intelligence Brief

MaaT013 (MaaT013) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microbiota therapeutic. Area: Immunology / Gastroenterology.

phase 3 Microbiota therapeutic Immunology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

MaaT013 (MaaT013) — MaaT Pharma. MaaT013 is a microbiota-based therapeutic that restores a healthy gut microbiome composition to treat immune-mediated diseases.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
MaaT013 TARGET	MaaT013	MaaT Pharma	phase 3	Microbiota therapeutic
Fecal Microbiota Transplantation	Fecal Microbiota Transplantation	University of California, Los Angeles	marketed	Biologic microbiota therapeutic
Human fecal microbiota, MBiotix HBI	Human fecal microbiota, MBiotix HBI	Medical University of Warsaw	phase 3	Microbiota therapeutic / Fecal microbiota transplant (FMT)
Fecal Microbial Transplantation	Fecal Microbial Transplantation	ProgenaBiome	phase 3	Biotherapeutic microbiota therapeutic
Fecal transplantation	Fecal transplantation	Bogomolets National Medical University	phase 3	Microbiota therapeutic
Encapsulated FMT	Encapsulated FMT	King's College London	phase 3	Microbiota therapeutic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microbiota therapeutic class)

Bogomolets National Medical University · 1 drug in this class
King's College London · 1 drug in this class
MaaT Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MaaT013 — Competitive Intelligence Brief. https://druglandscape.com/ci/maat013. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab